Introduction
============

Nicotinamide phosphoribosyltransferase (*Nampt*) is a novel adipokine, which has been reported to be expressed in adipose tissue, chondrocytes in the articular cartilage matrix and peripheral blood mononuclear cells (PBMCs) ([@b1-mmr-15-02-0784]--[@b4-mmr-15-02-0784]). It has been revealed that *Nampt* is closely associated with various biological processes, including nicotinamide adenine dinucleotide (NAD) biosynthesis, cellular metabolism and immunomodulatory responses. In the process of NAD biosynthesis, *Nampt* regulates the activity of the NAD-dependent deacetylase silent information regulator 2 (Sir2) through increasing the cellular level of NAD, and subsequently promoting Sir2 transcriptional activity in mammalian cells ([@b5-mmr-15-02-0784]). The potent *Nampt* inhibitor FK866 negatively regulates glycolysis by altering the initial steps in glucose oxidation and leads to changes in carbohydrate metabolism in cancer cells ([@b6-mmr-15-02-0784]). Furthermore, *Nampt* is an essential catabolic mediator of osteoarthritis, which is the most common form of inflammatory arthritis, and regulates hypoxia-inducible factor 2α-mediated matrix metalloproteinase (*MMP*) expression in chondrocytes, leading to the destruction of osteoarthritic cartilage ([@b7-mmr-15-02-0784]).

For the treatment of metabolic bone diseases, including osteoporosis, adipokines are considered to be a therapeutic target via their effects on two types of bone cell, osteoclasts and osteoblasts ([@b8-mmr-15-02-0784]). Osteoclasts are well-characterized cells that are required for bone resorption and excessive osteoclast differentiation is a predominant indicator of osteoporosis. Osteoblasts are responsible for bone formation. A previous study indicated that osteoblast proliferation and differentiation are enhanced *in vitro*, and that acceleration of bone formation and mineral apposition rates are observed *in vivo* in the absence of the adipokine apelin, which is a ligand of the Gi-G protein-coupled receptor APJ. These data suggest a crucial role of apelin in bone homeostasis as a physiological antianabolic factor ([@b9-mmr-15-02-0784]). Another adipokine, visceral adipose tissue-derived serine protease inhibitor (*vaspin*), has been reported to suppress receptor activator of nuclear factor-κB ligand (RANKL)-mediated differentiation of RAW264.7 cells and bone marrow cells (BMCs) into mature osteoclasts by reducing the expression of nuclear factor of activated T cells, cytoplasmic 1 (*NFATc1*) and the subsequent induction of osteoclast-specific gene markers, such as *MMP-9* and cathepsin K ([@b10-mmr-15-02-0784]). Adiponectin is an important adipokine that regulates energy homeostasis, which also inhibits RANKL-induced osteoclastogenesis by decreasing the expression of several osteoclastogenic factors, including *NFATc1*, tumor necrosis factor receptor-associated factor 6, cathepsin K and tartrate-resistant acid phosphatase (*TRAP*), and induces apoptosis in mature osteoclasts ([@b11-mmr-15-02-0784]). It has previously been demonstrated that *Nampt* attenuates osteoclast differentiation derived from PBMCs in patients with multiple myeloma and human CD14^+^ monocytes; however, the role of Nampt in the differentiation of murine bone marrow macrophages (BMMs) into osteoclasts and its underlying mechanisms have not yet been revealed ([@b12-mmr-15-02-0784],[@b13-mmr-15-02-0784]).

The present study investigated the effects of *Nampt* on RANKL-mediated osteoclast differentiation and functional bone-resorbing activity. In addition, the present study determined whether *Nampt* is involved in RANKL-dependent intracellular signaling pathways and the expression of osteoclast-specific gene markers.

Materials and methods
=====================

### Preparation of Nampt and reagents

Recombinant mouse *Nampt* (visfatin/pre-B-cell colony-enhancing factor) was purchased from Adipogen International, Inc. (San Diego, CA, USA). Recombinant soluble human macrophage colony-stimulating factor (M-CSF) and human RANKL were obtained from PeproTech EC Ltd. (London, UK). Anti-p38 (cat. no. 9212), anti-phosphorylated (p)-p38 (cat. no. 9211), anti-extracellular signal-regulated protein kinases (ERK) 1/2 (cat. no. 9102), anti-p-ERK 1/2 (cat. no. 9101), anti-c-Jun N-terminal kinase (JNK; cat. no. 9252), anti-p-JNK (cat. no. 9251), anti-Akt (cat. no. 9272), anti-p-Akt (cat. no. 9271), anti-glycogen synthase kinase-3 β (GSK3β; cat. no. 9315), anti-p-GSK3β (cat. no. 9323) and anti-Bruton\'s tyrosine kinase (Btk; cat. no. 3533) antibodies were purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA). Anti-c-Fos (cat. no. sc-7202), anti-NFATc1 (cat. no. sc-7294), anti-phospholipase C γ-2 (PLCγ2; cat. no. sc-5283) and anti-p-PLCγ2 (cat. no. sc-101785) antibodies were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Anti-p-Btk (cat. no. GTX61792) and monoclonal anti-β-actin (cat. no. GTX109639) antibodies were obtained from GeneTex, Inc. (Irvine, CA, USA) and Sigma-Aldrich (Merck Millipore; Darmstadt, Germany), respectively. Fetal bovine serum (FBS), α-minimum essential medium (α-MEM) and penicillin/streptomycin were purchased from Gibco (Thermo Fisher Scientific, Inc., Waltham, MA, USA). All other chemicals were of analytical grade or complied with the standards required for cell culture experiments.

### Mouse BMM preparation and osteoclast differentiation

A total of 10 male ICR strain mice (age, 5 weeks; weight, 30±2 g) were purchased from Samtako (Osan, Korea). During the experimental period, the mice were maintained in a temperature- and humidity-controlled environment at 22--24°C and 55--60% humidity, with a 12-h light/dark cycle and access to sterilized water and standard rodent chow (Samtako) *ad libitum*. All experiments were conducted according to the guidelines of the Institutional Animal Care and Use Committee of Wonkwang University (WKU-14-23; Iksan, Korea). BMMs from mice were cultured as described previously ([@b14-mmr-15-02-0784]). Briefly, to obtain BMMs, BMCs were cultured in α-MEM supplemented with 10% FBS and M-CSF (10 ng/ml) for 1 day. Non-adherent cells were further cultured in the presence of M-CSF (30 ng/ml) for 3 days. Subsequently, the adherent cells were used as BMMs. BMMs were cultured in 48-well plates at 37°C in 5% CO~2~ for 4 days in the condition of M-CSF (30 ng/ml) and RANKL (100 ng/ml), and pretreated with *Nampt* (100, 250 or 500 ng/ml). The cells were fixed in 3.7% formalin, permeabilized with 0.1% Triton X-100, and stained with TRAP solution. The stained multinucleated cells (MNCs) with \>5 nuclei were counted to determine the level of osteoclast differentiation.

### Cell viability assay, western blotting, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis and bone resorption assay

The XTT cell viability assay, western blot analysis, RT-qPCR analysis and the resorption pit assay were performed as described previously ([@b14-mmr-15-02-0784]). Resorption pits were imaged and analyzed using Image Pro-Plus version 4.5 (Media Cybernetics, Inc., Rockville, MD, USA). Primers used for PCR are summarized in [Table I](#tI-mmr-15-02-0784){ref-type="table"}. The western blots were analyzed using ImageJ ([imagej.nih.gov/](imagej.nih.gov/)).

### Retroviral gene transfection

Packaging of the retroviral vectors pMX-IRES-EGFP, pMX-cFos-IRES-EGFP and pMX-NFATc1-IRES-EGFP was performed using transient transfection of these pMX vectors (Cell Biolabs, Inc., San Diego, CA, USA) into platinum-E (plat-E) retroviral packaging cells (Cell Biolabs, Inc.) using X-tremeGENE 9 (Roche, Nutley, NJ, USA) according to the manufacturer\'s protocol. Following incubation at 37°C in fresh medium for 2 days, the culture supernatants of the retrovirus-producing cells were collected. For retroviral infection, non-adherent BMCs were cultured in M-CSF (30 ng/ml) for 2 days. The BMMs were incubated with viral supernatant medium of pMX-IRES-EGFP, pMX-cFos-IRES-EGFP and pMX-NFATc1-IRES-EGFP virus-producing plat-E cells together with polybrene (10 ng/ml) and M-CSF (30 ng/ml) for 6 h. The infection efficiency of the retrovirus was determined by green fluorescent protein (GFP) expression and was always \>80%. Post-infection, the BMMs were induced to differentiate in the presence of M-CSF (30 ng/ml) and RANKL (100 ng/ml) for 4 days. The expression of each construct was detected using a fluorescence microscope and osteoclast formation was determined by fixing in 3.7% formalin, permeabilizing with 0.1% Triton X-100, and staining with TRAP solution.

### Statistical analysis

Each experiment was performed at least three times and all quantitative data are presented as the mean ± standard deviation. All statistical analyses were performed using SPSS (Korean version 14.0; SPSS, Inc., Chicago, IL, USA). Student\'s t-test was used to compare the parameters between two groups, whereas the one-way analysis of variance test, followed by the Tukey post hoc test, was used to compare the parameters among three groups. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Nampt inhibits RANKL-mediated osteoclast formation in a dose-dependent manner with no cytotoxicity

The present study analyzed the expression of *Nampt* in BMM cultures treated with M-CSF (30 ng/ml) and RANKL (100 ng/ml). As shown in [Fig. 1A](#f1-mmr-15-02-0784){ref-type="fig"}, the mRNA expression levels of *Nampt* were reduced in the presence of RANKL. To validate the effects of *Nampt* on osteoclast differentiation, mouse primary BMMs were treated with M-CSF (30 ng/ml) and RANKL (100 ng/ml) in the presence or absence of various concentrations of Nampt. As expected, the control untreated group generated TRAP-positive (TRAP+) osteoclasts. However, the presence of *Nampt* suppressed the formation of TRAP+ multinucleated osteoclasts in a dose-dependent manner ([Fig. 1B and C](#f1-mmr-15-02-0784){ref-type="fig"}). Subsequently, XTT cell viability assays were conducted to ascertain whether *Nampt* induced cytotoxicity during RANKL-induced osteoclast differentiation. The addition of *Nampt* did not affect cell viability at any of the concentrations used in the present study ([Fig. 1D](#f1-mmr-15-02-0784){ref-type="fig"}).

### Nampt regulates osteoclastogenesis via mediating RANKL-dependent early signaling pathways

To elucidate a molecular mechanism that underlies the inhibitory effects of *Nampt* on osteoclastogenesis, *Nampt* was added to BMM cultures treated with M-CSF (30 ng/ml) and RANKL (100 ng/ml), at three different time points after RANKL treatment. The results indicated that *Nampt* (500 ng/ml) significantly blocked osteoclast differentiation when the cells were exposed on days 0--1 after RANKL treatment but not on days 1--2 or 2--3 ([Fig. 2A and B](#f2-mmr-15-02-0784){ref-type="fig"}). As shown in [Fig. 2C and D](#f2-mmr-15-02-0784){ref-type="fig"}, Nampt negatively affected the phosphorylation of JNK, Akt and GSK3β. In addition, *Nampt* downregulated the phosphorylation of Btk and PLCγ2, which are required for calcium signaling during osteoclast differentiation ([Fig. 2E and F](#f2-mmr-15-02-0784){ref-type="fig"}). These results indicated that *Nampt* is involved in the early stages of osteoclast differentiation by inducing dephosphorylation of JNK, Akt and its downstream target GSK3β, Btk and PLCγ2.

### Nampt downregulates the expression levels of c-Fos, NFATc1 and osteoclast-specific marker genes

To examine whether *Nampt* regulates RANKL-induced osteoclast differentiation by downregulating the activation of *c-Fos* and *NFATc1*, the present study evaluated the effects of *Nampt* on RANKL-induced *c-Fos* and *NFATc1* expression. When BMMs were stimulated for 12--48 h with RANKL (100 ng/ml), the mRNA expression levels of *c-Fos* and *NFATc1* were increased in the control group, whereas *Nampt* treatment reduced their expression ([Fig. 3A](#f3-mmr-15-02-0784){ref-type="fig"}). Similarly, western blot analysis demonstrated that *Nampt* significantly reduced the protein levels of c-Fos and NFATc1 ([Fig. 3B](#f3-mmr-15-02-0784){ref-type="fig"}). Subsequently, the present study examined whether ectopic expression of *c-Fos* or *NFATc1* is sufficient to rescue the inhibitory effects of *Nampt* on osteoclastogenesis using a retroviral system. BMMs were infected with *c-Fos* or *NFATc1*-encoding retroviruses and cultured with M-CSF (30 ng/ml) and RANKL (100 ng/ml) in the presence or absence of *Nampt* (500 ng/ml). Indeed, the overexpression of *c-Fos* or *NFATc1* rescued the anti-osteoclastogenic effect of *Nampt* ([Fig. 3C](#f3-mmr-15-02-0784){ref-type="fig"}). In addition, it was determined whether *Nampt* regulates the mRNA expression of various osteoclast-specific transcription factors, including *TRAP*, osteoclast associated receptor (*OSCAR*), cathepsin K, calcitonin receptor (*CTR*), *Atp6v0d2*, dendritic cell-specific transmembrane protein (*DC-STAMP*), αv-integrin and β3-integrin. These genes are associated with osteoclast formation and function during RANKL-induced osteoclast differentiation. The mRNA expression levels of *TRAP, OSCAR*, cathepsin K, *CTR, Atp6v0d2, DC-STAMP*, αv-integrin and β3-integrin were significantly decreased by *Nampt* ([Fig. 4](#f4-mmr-15-02-0784){ref-type="fig"}). These results suggested that *Nampt* efficiently inhibits c-Fos and NFATc1 activation, leading to the downregulation of osteoclast marker gene expression during RANKL-mediated osteoclast differentiation.

### Nampt is not associated with the bone-resorbing activity of mature osteoclasts

The present study subsequently examined whether *Nampt* regulates osteoclastic bone-resorptive functions. To investigate this role, mature osteoclasts were seeded onto the top of hydroxyapatite-coated plates in the presence or absence of *Nampt* (500 ng/ml). However, the number and area of resorption pits were unaffected by *Nampt* treatment ([Fig. 4](#f4-mmr-15-02-0784){ref-type="fig"}), suggesting that *Nampt* does not have a role in the resorbing activity of mature osteoclasts.

Discussion
==========

The present study demonstrated that *Nampt* attenuated RANKL-mediated differentiation of primary mouse BMMs into TRAP^+^ MNCs in a dose-dependent manner without cytotoxic effects. During this process, *Nampt* decreased the phosphorylation of various early signal transducers, including JNK and Akt, and its downstream target, GSK3β, as well as calcium-dependent signaling pathways, including PLCγ2 and Btk. Furthermore, the mRNA and protein expression levels of two master regulators of osteoclastogenesis, *c-Fos* and *NFATc1*, were significantly decreased by *Nampt* treatment, leading to decreased expression levels of various key transcription factors in osteoclast differentiation including *TRAP*, *OSCAR*, cathepsin K, *CTR*, *Atp6vOd2*, *DC-STAMP*, β3- and αv-integrin.

The differentiation of monocyte/macrophage lineage precursors into bone-resorbing osteoclasts is initiated in response to two important cytokines, M-CSF and RANKL, resulting in the activation of early downstream pathways ([@b15-mmr-15-02-0784]). During this process, the phosphorylation of numerous signal transducers, including mitogen-activated protein kinases (MAPKs), which are comprised of p38, ERK and JNK; nuclear factor-κB; phosphatidylinositol 3-kinase/Akt; PLCγ2 and Btk occurs ([@b16-mmr-15-02-0784]--[@b19-mmr-15-02-0784]). RANKL-mediated activation of JNK is known to have an anti-apoptotic function in osteoclastogenesis, and Akt is a potent inducer of osteoclast differentiation by promoting the formation of an inactive form of GSK3β (p-GSK3β) and the nuclear translocation of NFATc1 ([@b20-mmr-15-02-0784],[@b21-mmr-15-02-0784]). In addition, it has been well established that calcium signaling is crucial for RANKL-dependent osteoclastogenesis. PLCγ2 activation requires phosphorylation of its tyrosine residues to induce calcium oscillations and the translocation of NFATc1 by forming a complex with regulatory adapter molecule GRB2-associated binding protein 2 and modulating its recruitment to RANK ([@b22-mmr-15-02-0784],[@b23-mmr-15-02-0784]). PLCγ2 is regulated by the upstream tyrosine kinase Btk, which is involved in osteoclast differentiation by linking RANK and immunoreceptor tyrosine-based activation motif signaling, with subsequent regulation of the formation of Btk/BLNK-containing complex and activation of PLCγ2-dependent calcium signaling ([@b19-mmr-15-02-0784]). The results of the present study revealed that *Nampt* suppressed RANKL-induced osteoclast differentiation by interfering with survival-related signaling pathways that contain JNK and Akt, as well as Btk-PLCγ2-dependent intracellular calcium signaling. Since *Nampt* affected several signals associated with the early stages of osteoclastogenesis, the present study examined whether *Nampt* is involved in the expression of late-stage transcription factors, *c-Fos* and *NFATc1*. A previous report indicated that *c-Fos* knock-out mice exhibit morphological characteristics of osteopetrosis, owing to osteoclast malfunction, whereas impaired osteoclastogenesis in murine BMMs is completely rescued by exogenous overexpression of *c-Fos* ([@b24-mmr-15-02-0784],[@b25-mmr-15-02-0784]). In response to the activation of *c-Fos*, another master regulator, *NFATc1*, serves a crucial role in osteoclast differentiation. *NFATc1* inhibition in embryonic stem cells suppresses their ability to differentiate into normal osteoclasts, and this phenomenon is reversed by ectopic expression of *NFATc1* even in the absence of RANKL ([@b26-mmr-15-02-0784],[@b27-mmr-15-02-0784]). This c-Fos-NFATc1 activation cascade leads to the elevated expression of osteoclast-specific gene markers, such as *TRAP*, *OSCAR*, *CTR*, cathepsin K, *DC-STAMP* and β3-integrin. The present data revealed that *Nampt* expression significantly decreased mRNA and protein levels of c-Fos and NFATc1 compared with the control, resulting in the downregulation of various transcription factors associated with osteoclast formation and function.

Although the relationship between bone regulation and *Nampt* has previously been reported, the present study is the first, to the best of our knowledge, to identify the effects of *Nampt* on mouse BMM-derived osteoclastogenesis and its molecular mechanisms. In conclusion, the present study demonstrated that the adipokine *Nampt* effectively interferes with RANKL-mediated osteoclast differentiation by inactivating several early signal transducers. These signaling molecules include JNK, Akt and GSK3β, as well as Btk-PLCγ2-calcium signaling. Furthermore, *Nampt* treatment decreases c-Fos and NFATc1 mRNA and protein levels, resulting in the downregulation of various target gene mRNA levels. *Nampt* does not influence the bone-resorbing activity of mature osteoclasts; instead, *Nampt* exerts its anti-osteoclastogenic effects by targeting osteoclast precursors rather than mature multinucleated osteoclasts. Although further studies are required to reveal the restorative effect of *Nampt* on osteoporotic bone loss in mouse models, it may be suggested that increased *Nampt* is a potential target for the treatment of metabolic bone diseases, such as osteoporosis, by suppressing osteoclast differentiation and function.

The present study was supported by a grant from the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (grant no. NRF-2016R1D1A1B03933712).

![Nampt attenuates TRAP-positive osteoclast formation without cytotoxicity. (A) BMMs were cultured in the presence of M-CSF (30 ng/ml) and then stimulated with RANKL (100 ng/ml) for the indicated durations. Total RNA was isolated from cells using QIAzol reagent and Nampt mRNA levels were evaluated by reverse transcription-quantitative polymerase chain reaction. \*\*\*P\<0.001 vs. control group. (B) BMMs were cultured for 3 days in the presence of M-CSF (30 ng/ml) and RANKL (100 ng/ml), with or without the indicated concentrations of Nampt. Cells were fixed, permeabilized and stained with TRAP solution. Images of TRAP^+^ cells were captured under a light microscope (magnification, ×5). (C) BMMs were seeded into a 96-well plate and cultured for 3 days in the presence of M-CSF (30 ng/ml) with the indicated concentrations of Nampt (100, 250 or 500 ng/ml). After 3 days, cell viability was analyzed by the XTT assay. (D) TRAP^+^ MNCs with \>5 nuclei were counted as osteoclasts. \*\*\*P\<0.001 vs. control group. BMMs, bone marrow macrophages; M-CSF, macrophage colony-stimulating factor; MNCs, mononucleated cells; N, nuclei; Nampt, nicotinamide phosphoribosyltransferase; RANKL, receptor activator of nuclear factor-κB ligand; TRAP, tartrate-resistant acid phosphatase.](MMR-15-02-0784-g00){#f1-mmr-15-02-0784}

![Nampt inhibits the early stages of osteoclastogenesis by downregulating RANKL-dependent early signaling pathways. (A) BMMs were cultured for 3 days in the presence of M-CSF (30 ng/ml) and RANKL (100 ng/ml) with or without Nampt (500 ng/ml) for the indicated durations. Cells were then stained with TRAP solution and images of TRAP^+^ cells were captured under a light microscope (magnification, 5x). The diagram shows the time period of Nampt treatment. (B) TRAP^+^ MNCs with \>5 nuclei were counted as osteoclasts. \*\*\*P\<0.001 vs. control group. (C) BMMs were pretreated with or without Nampt (500 ng/ml) for 1 h in the presence of M-CSF (30 ng/ml) prior to RANKL (100 ng/ml) stimulation at the indicated time points. Whole-cell lysates were analyzed by western blotting with the indicated antibodies. β-actin was used as the internal control. (D) Semi-quantification of blots was performed using ImageJ. \*\*\*P\<0.001 vs. the control group (E) BMMs were pretreated with or without of Nampt (500 ng/ml) for 1 h in the presence of M-CSF (30 ng/ml) prior to RANKL (100 ng/ml) stimulation at the indicated time points. Whole-cell lysates were analyzed by western blotting with the indicated antibodies. β-actin was used as the internal control. (F) Semi-quantification of western blot bands was performed using ImageJ. \*\*\*P\<0.001 vs. the control group. BMMs, bone marrow macrophages; Btk, Bruton\'s tyrosine kinase; ERK, extracellular signal-regulated protein kinases; GSK3β, glycogen synthase kinase-3 β; JNK, c-Jun N-terminal kinase; M-CSF, macrophage colony-stimulating factor; MNCs, mononucleated cells; N, nuclei; Nampt, nicotinamide phosphoribosyltransferase; p-, phosphorylated; PLCγ2, phospholipase C γ-2 RANKL, receptor activator of nuclear factor-κB ligand; TRAP, tartrate-resistant acid phosphatase.](MMR-15-02-0784-g01){#f2-mmr-15-02-0784}

![Nampt reduces the expression of c-Fos and NFATc1. (A) BMMs were pretreated with or without Nampt (500 ng/ml) for 1 h in the presence of M-CSF (30 ng/ml), and then stimulated with RANKL (100 ng/ml) for the indicated times. The mRNA expression levels of c-Fos and NFATc1 were analyzed by reverse transcription-quantitative polymerase chain reaction. \*P\<0.05, \*\*\*P\<0.001 vs. control group at the indicated time points. (B) The effects of Nampt on protein levels of c-Fos and NFATc1 were evaluated by western blot analysis with the indicated antibodies. β-actin was used as the internal control. (C) BMMs were infected with retroviruses expressing pMX-IRES-EGFP (pMX), pMX-cFos-IRES-EGFP (c-Fos) or pMX-NFATc1-IRES-EGFP (NFATc1). Infected BMMs were cultured with or without Nampt (500 ng/ml) in the presence of M-CSF (30 ng/ml) and RANKL (100 ng/ml) for 4 days. After culturing, the cells were stained with TRAP solution. Images of TRAP^+^ cells were captured under a light microscope (magnification, 5x). TRAP^+^ MNCs with \>5 nuclei were counted as osteoclasts. \*\*\*P\<0.001 vs. control group and ^\#\#\#^P\<0.001 vs. Nampt group. BMMs, bone marrow macrophages; M-CSF, macrophage colony-stimulating factor; MNCs, mononucleated cells; N, nuclei; Nampt, nicotinamide phosphoribosyltransferase; NFATc1, nuclear factor of activated T cells, cytoplasmic 1; RANKL, receptor activator of nuclear factor-κB ligand; TRAP, tartrate-resistant acid phosphatase.](MMR-15-02-0784-g02){#f3-mmr-15-02-0784}

![Nampt reduces the expression of osteoclast-specific genes. BMMs were pretreated with or without Nampt (500 ng/ml) for 1 h in the presence of M-CSF (30 ng/ml) and then stimulated with RANKL (100 ng/ml) for the indicated times. Total RNA was isolated from cells using QIAzol reagent and the mRNA expression levels of TRAP, OSCAR, cathepsin K, CTR, Atp6vOd2, DC-STAMP, β3-integrin and αv-integrin were evaluated by reverse transcription-quantitative polymerase chain reaction. \*\*\*P\<0.001 vs. control group at the indicated time. BMMs, bone marrow macrophages; CTR, calcitonin receptor; DC-STAMP, dendritic cell-specific transmembrane protein; M-CSF, macrophage colony-stimulating factor; Nampt, nicotinamide phosphoribosyltransferase; OSCAR, osteoclast-associated receptor; RANKL, receptor activator of nuclear factor-κB ligand; TRAP, tartrate-resistant acid phosphatase.](MMR-15-02-0784-g03){#f4-mmr-15-02-0784}

![Nampt does not affect the bone-resorbing activity of mature osteoclasts. Mature osteoclasts were seeded on hydroxyapatite-coated plates and treated for 24 h with Nampt (500 ng/ml). Attached cells were removed and images were captured under a light microscope (magnification, ×5). Pit areas on the hydroxyapatite plate were quantified using the Image Pro-Plus (version 4.5) software. Nampt, nicotinamide phosphoribosyltransferase.](MMR-15-02-0784-g04){#f5-mmr-15-02-0784}

###### 

Primer sequences used for reverse transcription-quantitative polymerase chain reaction analysis.

  Gene            Primer sequence (5′-3′)
  --------------- --------------------------------
  *GAPDH*         
    Forward       5′-TCAAGAAGGTGGTGAAGCAG-3′
    Reverse       5′-AGTGGGAGTTGCTGTTGAAGT-3′
  *c-Fos*         
    Forward       5′-GGTGAAGACCGTGTCAGGAG-3′
    Reverse       5′-TATTCCGTTCCCTTCGGATT-3′
  *NFATc1*        
    Forward       5′-GAGTACACCTTCCAGCACCTT-3′
    Reverse       5′-TATGATGTCGGGGAAAGAGA-3′
  *TRAP*          
    Forward       5′-TCATGGGTGGTGCTGCT-3′
    Reverse       5′-GCCCACAGCCACAAATCT-3′
  *OSCAR*         
    Forward       5′-GGAATGGTCCTCATCTCCTT-3′
    Reverse       5′-TCCAGGCAGTCTCTTCAGTTT-3′
  *DC-STAMP*      
    Forward       5′-TCCTCCATGAACAAACAGTTCCA-3′
    Reverse       5′-AGACGTGGTTTAGGAATGCAGCTC-3′
  *Atp6vOd2*      
    Forward       5′-GACCCTGTGGCACTTTTTGT-3′
    Reverse       5′-GTGTTTGAGCTTGGGGAGAA-3′
  *Cathepsin K*   
    Forward       5′-CCAGTGGGAGCTATGGAAGA-3′
    Reverse       5′-CTCCAGGTTATGGGCAGAGA-3′
  αv-integrin     
    Forward       5′- ACAAGCTCACTCCCATCACC-3′
    Reverse       5′- ATATGAGCCTGCCGACTGAC-3′
  β3-integrin     
    Forward       5′-GGAGTGGCTGATCCAGATGT-3′
    Reverse       5′-TCTGACCATCTTCCCTGTCC-3′
  *CTR*           
    Forward       5′-TCCAACAAGGTGCTTGGGAA-3′
    Reverse       5′-CTTGAACTGCGTCCACTGGC-3′
  *Nampt*         
    Forward       5′-ATCCAGGAGGCCAAAGAAGT-3′
    Reverse       5′-CGGGAGATGACCATCGTATT-3′

*CTR*, calcitonin receptor; *DC-STAMP*, dendritic cell-specific transmembrane protein; *Nampt*, nicotinamide phosphoribosyltransferase; *NFATc1*, nuclear factor of activated T cells, cytoplasmic 1; *OSCAR*, osteoclast-associated receptor; *TRAP*, tartrate-resistant acid phosphatase.

[^1]: Contributed equally
